G1T48: Experimental Treatment for Estrogen Receptor-Positive, HER2-negative (ER+, HER2-) Breast Cancer
Scientific rationale and therapeutic potential
G1T48 is an oral selective estrogen receptor degrader (SERD) designed to inhibit estrogen receptor driven tumor growth as a single agent and in combination with other anti-cancer therapies, including CDK 4/6 inhibitors such as G1T38. G1T48 has the potential to be a best-in-class oral SERD.
Preclinical results (see: Publications)
- published preclinical data demonstrating G1T48 to be more potent than Faslodex® and to have superior anti-tumor efficacy versus other SERDs in development;
- this is the first clinical trial of G1T48 in ER+, HER2- breast cancer.
G1 is recruiting patients for a Phase 1/2a trial in ER+, HER2- breast cancer